Subject(s)
Intubation, Intratracheal , Wakefulness , Adult , Fiber Optic Technology , Humans , RemifentanilABSTRACT
Zebu (Bos indicus) is a domestic cattle species originating from the Indian subcontinent and now widely domesticated on several continents. In this study, we were particularly interested in understanding the functionally active rumen microbiota of an important Zebu breed, the Gir, under different dietary regimes. Metagenomic and metatranscriptomic data were compared at various taxonomic levels to elucidate the differential microbial population and its functional dynamics in Gir cattle rumen under different roughage dietary regimes. Different proportions of roughage rather than the type of roughage (dry or green) modulated microbiome composition and the expression of its gene pool. Fibre degrading bacteria (i.e. Clostridium, Ruminococcus, Eubacterium, Butyrivibrio, Bacillus and Roseburia) were higher in the solid fraction of rumen (P<0.01) compared to the liquid fraction, whereas bacteria considered to be utilizers of the degraded product (i.e. Prevotella, Bacteroides, Parabacteroides, Paludibacter and Victivallis) were dominant in the liquid fraction (P<0.05). Likewise, expression of fibre degrading enzymes and related carbohydrate binding modules (CBMs) occurred in the solid fraction. When metagenomic and metatranscriptomic data were compared, it was found that some genera and species were transcriptionally more active, although they were in low abundance, making an important contribution to fibre degradation and its further metabolism in the rumen. This study also identified some of the transcriptionally active genera, such as Caldicellulosiruptor and Paludibacter, whose potential has been less-explored in rumen. Overall, the comparison of metagenomic shotgun and metatranscriptomic sequencing appeared to be a much richer source of information compared to conventional metagenomic analysis.
Subject(s)
Animal Feed/analysis , Bacteria/classification , Diet , Rumen/microbiology , Animals , Bacteria/genetics , Cattle , Metagenome/genetics , Metagenomics/methods , Microbiota/geneticsSubject(s)
Birth Injuries , Eye Injuries , Obstetric Labor Complications/surgery , Obstetrical Forceps/adverse effects , Ophthalmologic Surgical Procedures/methods , Retinal Detachment , Vision Disorders/etiology , Birth Injuries/diagnosis , Birth Injuries/etiology , Birth Injuries/surgery , Diagnostic Techniques, Ophthalmological , Eye Injuries/diagnosis , Eye Injuries/etiology , Eye Injuries/surgery , Female , Humans , Infant, Newborn , Male , Pregnancy , Retinal Detachment/diagnosis , Retinal Detachment/etiology , Retinal Detachment/surgery , Treatment OutcomeABSTRACT
There are many negative health consequences associated with alcohol dependency. Fractures of the proximal femur carry significant morbidity and mortality. This study examines the outcomes in patients with alcohol dependency, who sustain a fracture of the proximal femur. Twenty-eight consecutive alcohol dependent patients who suffered a fracture of the proximal femur were identified over a three year period. Data were collected on demographics, co-morbidity, surgical factors, mobility and mortality. The median age of patients was 61 years. The median weekly alcohol intake was 158 units. Thirteen patients sustained an extra-capsular fracture and 15 an intra-capsular proximal femoral fracture. Twenty-two fractures were treated with internal fixation and six with arthroplasty. The overall mortality rate was 29% at a median of 15 months post fracture. The failure rate of intra-capsular fractures fixed with cannulated screws was 56% at a median time of 43 days. All patients had a reduction in mobility compared to their pre-operative function. The reduction in mobility was greatest in patients with intra-capsular fractures treated with cannulated screw fixation. Alcohol dependent patients sustaining a fracture of the proximal femur are significantly younger than non-alcohol dependent patients sustaining the same injury. Despite the younger age at presentation the one year mortality rate of this group was high (29%). The high rate of complications with fracture fixation and high one year mortality suggest that hemiarthroplasty may be the best treatment option for intra-capsular fractures in this patient group.
Subject(s)
Alcoholism/complications , Bone Screws , Femoral Fractures/mortality , Femoral Fractures/surgery , Hemiarthroplasty , Adult , Aged , Comorbidity , Female , Follow-Up Studies , Hemiarthroplasty/methods , Hemiarthroplasty/mortality , Humans , Male , Middle Aged , Patient Compliance , Survival Analysis , United Kingdom/epidemiologyABSTRACT
Cardiovascular disease is the leading cause of morbidity and mortality in maintenance hemodialysis (MHD) patients. We evaluated the role of serum catalytic iron (SCI) as a biomarker for coronary artery disease (CAD) in patients on MHD. SCI was measured in 59 stable MHD patients. All patients underwent coronary angiography. Significant CAD was defined as a > 70% narrowing in at least one epicardial coronary artery. Levels of SCI were compared with a group of healthy controls. Significant CAD was detected in 22 (37.3%) patients, with one vessel disease in 14 (63.63%) and multi-vessel disease in eight (36.36%) patients. The MHD patients had elevated levels of SCI (4.70 ± 1.79 µmol/L) compared with normal health survey participants (0.11 ± 0.01 µmol/L) (P < 0.0001). MHD patients who had no CAD had SCI levels of 1.36 ± 0.34 µmol/L compared with those having significant CAD (8.92 ± 4.12 µmol/L) (P < 0.0001). Patients on MHD and diabetes had stronger correlation between SCI and prevalence of CAD compared with non-diabetics. Patients having one vessel disease had SCI of 8.85 ± 4.67 µmol/L versus multi-vessel disease with SCI of 9.05 ± 8.34 µmol/L, P = 0.48. In multivariate analysis, SCI and diabetes mellitus were independently associated with significant CAD. We confirm the high prevalence of significant CAD in MHD patients. Elevated SCI levels are associated with presence of significant coronary disease in such patients. The association of SCI is higher in diabetic versus the non-diabetic subgroup. This is an important potentially modifiable biomarker of CAD in MHD patients.
ABSTRACT
BACKGROUND: Tongue cancer is one of the common cancers in head and neck region. Cervical node metastasis is the strongest poor prognostic factor. Other prognostic factors were also said to be of significance. Our aim was to find out the significant prognostic factors of tumor aggressiveness in Indian perspective. MATERIAL AND METHODS: Sixty cases of early cancer of oral tongue with clinically non palpable neck nodes were managed by upfront surgery. Surgeries performed for the primary tumor were 'wide excision' or 'hemiglossectomy' along with neck dissection. Patients were then given post-operative radiotherapy according to standard guidelines. They were analyzed using a detailed proforma. Three patients were lost to follow-up rest all patients were followed. RESULTS: Recurrence was seen in 11 out of 60 patients (18.3%), in an average follow-up period of about 28 months. Among those who recurred, one patient had both nodal and local recurrence, 2 patients had nodal only (regional) recurrence and rest 8 patients had local recurrence. The prognostic factors that significantly affected the recurrence were endo-phytic disease, depth of invasion, lymphatic invasion, muscle invasion, healthy margin and adjuvant radiotherapy. CONCLUSION: The risk factors for recurrence in early lesions of oral tongue are - Cervical nodal metastasis, Lymphatic permeation, Depth of disease - 6 mm or more, poorly differentiated tumor, Endophytic (infiltrative) disease, Young age at presentation and Muscle invasion. In early tongue lesions, that are node negative, selective node dissection (SND) including level 1, 2, 3 and 4, is a viable option for neck to decrease the morbidity of MND.
ABSTRACT
An increased number of thalassaemia patients treated with effective chelation therapy protocols are achieving body iron levels similar to those of normal individuals. Iron chelation therapy has also been recently used in a number of other categories of patients with no excess body iron load such as neurodegenerative, renal and infectious diseases. Chelation therapy in the absence of iron overload in the latter conditions raises many safety issues including chelator overdose toxicity and toxicity related to iron and other essential metal deficiencies. Preliminary preclinical and clinical toxicity evidence suggest that deferoxamine and deferasirox can only be safely used for these non-iron loaded conditions for short-term treatments of a few weeks, whereas deferiprone can be used for longer term treatments of many months. The selection of the chelating drug and appropriate dose protocols for targeting specific organs and conditions is critical for the safety of patients with normal iron stores. Chelation therapy is likely to play a major role as adjuvant, alternative or main therapy in many non-iron loading conditions in the forthcoming years.
Subject(s)
Chelation Therapy/adverse effects , Communicable Diseases , Iron Chelating Agents/adverse effects , Kidney Diseases , Neurodegenerative Diseases , Thalassemia , Clinical Trials as Topic , Communicable Diseases/blood , Communicable Diseases/drug therapy , Humans , Iron , Iron Overload/blood , Iron Overload/drug therapy , Kidney Diseases/blood , Kidney Diseases/drug therapy , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/drug therapy , Reference Values , Thalassemia/blood , Thalassemia/drug therapyABSTRACT
A man in his 70s presented with bilateral, painful legs and feeling generally unwell following the seasonal flu vaccination. The patient had a background of B cell lymphoma in partial remission. His current medications included simvastatin. Initial investigations revealed rhabdomyolysis and acute renal failure. He was admitted to critical care for renal replacement treatment. Other causes of rhabdomyolysis were excluded and expert opinion agreed that the most likely cause was the influenza vaccination with the concurrent use of simvastatin. The patient's renal function gradually normalised and after several months the patient has regained full power in his legs.
Subject(s)
Acute Kidney Injury/chemically induced , Influenza Vaccines/adverse effects , Rhabdomyolysis/chemically induced , Simvastatin/adverse effects , Acute Kidney Injury/diagnosis , Acute Kidney Injury/therapy , Aged , Anti-Bacterial Agents/therapeutic use , Creatinine/blood , Critical Illness/therapy , Follow-Up Studies , Hemofiltration/methods , Humans , Influenza Vaccines/administration & dosage , Influenza, Human/parasitology , Intensive Care Units , Kidney Function Tests , Lymphoma, B-Cell/diagnosis , Lymphoma, B-Cell/drug therapy , Male , Rhabdomyolysis/physiopathology , Rhabdomyolysis/therapy , Risk Assessment , Simvastatin/therapeutic use , Treatment Outcome , Vaccination/adverse effectsSubject(s)
Anniversaries and Special Events , Global Health , Kidney Diseases , Foundations , Health Promotion , Humans , Information Dissemination , International Cooperation , Kidney Diseases/diagnosis , Kidney Diseases/epidemiology , Kidney Diseases/prevention & control , Patient Education as Topic , Program DevelopmentABSTRACT
Nephrogenic systemic fibrosis is a severe disabling disease that can follow gadolinium-based contrast exposure. In this study we analyzed the clinical and laboratory records of patients with nephrogenic systemic fibrosis who had a history of exposure to gadolinium-based contrast media and identified their cardiac and vascular events. At autopsy, we found that the heart, blood vessels, and skin of three patients who died of cardiac and/or vascular complications had appreciable amounts of gadolinium, iron, and aluminum as measured by inductively coupled plasma-mass spectrometry and confirmed by x-ray fluorescence. Of the 32 patients with nephrogenic systemic fibrosis studied, 10 died at a median of 112 days after diagnosis. Cardiovascular events contributed to the mortality of 9 patients and included congestive heart failure, recurrent arrhythmias, hypotension, stroke, limb ischemia, posterior ischemic optic neuropathy and sudden death. Our results show that increased cardiac and vascular complications along with short survival in nephrogenic systemic fibrosis are associated with metal accumulation in the heart, blood vessels, and skin of these patients.
Subject(s)
Cardiovascular Diseases/mortality , Cardiovascular Diseases/pathology , Contrast Media/adverse effects , Gadolinium/adverse effects , Kidney Diseases/complications , Kidney Diseases/pathology , Adult , Aged , Aged, 80 and over , Autopsy , Blood Vessels/metabolism , Blood Vessels/pathology , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/metabolism , Contrast Media/metabolism , Female , Fibrosis , Gadolinium/metabolism , Humans , Kidney Diseases/metabolism , Liver/metabolism , Liver/pathology , Male , Middle Aged , Myocardium/metabolism , Myocardium/pathology , Skin/metabolism , Skin/pathology , Tissue DistributionABSTRACT
This study examined the role of cisplatin-induced p53 activation in regulation of caspases and cellular injury during cisplatin nephrotoxicity. The executioner caspase-6 and -7 but not caspase-3 were identified as transcriptional targets of p53 in cisplatin injury as revealed by chromatin immunoprecipitation, a reporter gene and electrophoretic mobility shift assays, and real-time PCR following overexpression and inhibition of p53. DNA binding by p53 involved the first introns of the human and mouse caspase-7 gene and the mouse caspase-6 gene. Studies in human kidney, breast, ovary, colon, and prostate tumor cell lines also validated these findings. Treatment of p53 (-/-) cells with cisplatin did not induce caspase-6 and -7 expression and subsequent activation. In caspase-3 (-/-) cells, inhibition of caspase-6 and -7 activations markedly prevented cisplatin-induced cell death. In an in vivo model of cisplatin nephrotoxicity inhibition of p53 activation by a p53 inhibitor suppressed transactivation of the caspase-6 and -7 genes and prevented renal failure. p53 (-/-) mice were resistant to cisplatin nephrotoxicity as assessed by renal function and histology. These studies provide first evidence for p53-dependent transcriptional control of the caspase-6 and -7 genes and its functional significance in cisplatin injury to renal cells and functional implication of cisplatin-induced p53 induction in vitro and in vivo in cisplatin nephrotoxicity.
Subject(s)
Antineoplastic Agents/toxicity , Caspase 6/genetics , Caspase 7/genetics , Cisplatin/toxicity , Kidney Tubules/drug effects , Transcriptional Activation , Tumor Suppressor Protein p53/metabolism , Animals , Apoptosis , Caspase 6/biosynthesis , Caspase 7/biosynthesis , Caspase Inhibitors , Caspases/biosynthesis , Caspases/genetics , Cell Line, Tumor , Cells, Cultured , Humans , Kidney/drug effects , Kidney/enzymology , Kidney Tubules/cytology , Kidney Tubules/metabolism , Mice , Mice, Knockout , RNA, Messenger/biosynthesis , Renal Insufficiency/chemically induced , Tumor Suppressor Protein p53/antagonists & inhibitors , Tumor Suppressor Protein p53/geneticsABSTRACT
Meprins are zinc-dependent metalloproteinases that are highly expressed in the brush-border membranes of both the kidney and the intestines. Meprins are capable of proteolytically degrading extracellular matrix proteins, proteolytically processing bioactive proteins, and play a role in inflammatory processes. In this study, the function of meprin A in the acute kidney injury (AKI) model of cisplatin nephrotoxicity was examined. Normal linear localization of meprin A in the brush border membranes of proximal tubules was altered in AKI. The meprin A alpha-subunit was detected in the urine of both control and cisplatin-treated mice. A cleaved product of the meprin A beta-subunit, undetected in the urine of control mice, was found to be significantly increased in the urine during the progression of cisplatin nephrotoxicity. The excretion of this beta-fragment was found to be before the rise in serum creatinine and blood urea nitrogen (BUN) suggesting usefulness as a biomarker for AKI. Pretreatment of mice with a meprin A inhibitor afforded protection from cisplatin nephrotoxicity as reflected by significant decreases in serum creatinine, BUN, and the excretion of kidney injury molecule-1. These decreases in serum and urine biomarkers were accompanied by significant decreases in histologic markers such as leukocyte infiltration and apoptosis. Meprin A appears to be an important therapeutic target and urinary excretion appears to be a potential biomarker of AKI.
Subject(s)
Kidney Diseases/enzymology , Kidney Diseases/pathology , Kidney Tubules/enzymology , Kidney Tubules/pathology , Metalloendopeptidases/metabolism , Acute Disease , Animals , Apoptosis/drug effects , Cisplatin , Hepatitis A Virus Cellular Receptor 1 , Hydroxamic Acids/pharmacology , Kidney/drug effects , Kidney/pathology , Kidney/physiopathology , Kidney Diseases/chemically induced , Kidney Diseases/physiopathology , Leukocytes/pathology , Membrane Glycoproteins/metabolism , Metalloendopeptidases/antagonists & inhibitors , Metalloendopeptidases/deficiency , Metalloendopeptidases/urine , Mice , Mice, Inbred C57BL , Mice, Knockout , Microvilli/metabolism , Protein Isoforms/urine , Receptors, Virus/metabolism , Tissue DistributionABSTRACT
We report a case of an obscure injury to the distal femoral epiphysis with an uncommon pattern in a 12-year-old boy following a road traffic accident. Initial plain radiographs of the knee were inconclusive. Further investigation with magnetic resonance imaging revealed Salter-Harris type III fracture of the lateral femoral condyle with a gap at the fracture site associated with avulsion of the posterior cruciate ligament. This potentially serious injury can be underestimated on plain radiographs and therefore any suspected injury to the distal femoral epiphysis should be thoroughly assessed and investigated to institute appropriate treatment and minimise the risk of long-term complications.
Subject(s)
Femoral Fractures/diagnosis , Fractures, Closed/diagnosis , Posterior Cruciate Ligament/injuries , Accidents, Traffic , Ankle Injuries/diagnosis , Ankle Injuries/therapy , Child , Epiphyses/injuries , Epiphyses/surgery , Femoral Fractures/pathology , Femoral Fractures/surgery , Follow-Up Studies , Fractures, Closed/pathology , Fractures, Closed/surgery , Humans , Magnetic Resonance Imaging , Male , Posterior Cruciate Ligament/surgeryABSTRACT
Two brothers with immune-mediated myasthenia gravis are presented for the rarity. The clinical presentation was dissimilar. Both had acetylcholine receptor antibody positivity and one had thymoma. Both responded to immunomodulation and thymectomy. Relevant literature is reviewed.
Subject(s)
Myasthenia Gravis/genetics , Siblings , Adult , Cholinergic Antagonists/therapeutic use , Diagnosis, Differential , Genetic Predisposition to Disease , Humans , Male , Myasthenia Gravis/complications , Myasthenia Gravis/drug therapy , Receptors, Cholinergic/immunology , Thymectomy , Thymoma/complications , Thymoma/immunologyABSTRACT
BACKGROUND: Cellular and molecular mechanisms responsible for cisplatin-induced nephrotoxicity to renal tubular epithelial cells are not well understood. Although caspases play a critical role in the execution of the cell death pathway, their specific role in toxic injury to renal tubular epithelial cells has not been elucidated previously. METHODS: The role of caspases in cisplatin-induced injury was determined using caspase inhibitors and p35 transfected LLC-PK1 cells. The Akt/PKB phosphorylation pathway was studied for the regulation of caspase activation in these cells. RESULTS: The activation of initiator caspases-8, -9 and -2, and executioner caspase-3 began after eight hours of cisplatin treatment, thereafter markedly increased in a time (8 to 24 hours) and dose-dependent manner (0 to 200 micromol/L). Proinflammatory caspase-1 did not show cisplatin-induced activation. Inhibition of caspase-3 by over expressing cowpox virus p35 protein or alternatively by the peptide inhibitor DEVD-CHO provided marked protection against cell death and partial protection against DNA damage. We then examined the role of the Akt/PKB phosphorylation pathway in regulation of cisplatin-induced caspase activation. There was a marked induction of Akt/PKB phosphorylation in a time (0 to 8 hours) and dose-dependent (0 to 200 micromol/L) manner during the course of cisplatin injury. Cisplatin-induced Akt/PKB activation was associated with Bad phosphorylation, suggesting induction of a cell survival signal mediated by the Bcl-2 family member, Bad. Wortmannin or LY294002, two structurally dissimilar inhibitors of phosphatidylinositol 3'-kinase (PI-3 kinase), abolished both cisplatin-induced Akt phosphorylation and Bad phosphorylation, and promoted cisplatin-induced early and accelerated activation of caspase-3 and caspase-9, but not of caspase-8 and caspase-1, indicating that inhibition of the Akt/PKB phosphorylation pathway enhances the mitochondrial-dependent activation of caspases. The impact of enhanced activation of caspases by wortmannin or LY294002 was reflected on accelerated cisplatin-induced cell death. CONCLUSIONS: These studies demonstrate differential activation and role of caspases in cisplatin injury, and provide the first evidence of cisplatin-induced induction of the Akt/PKB phosphorylation pathway, inhibition of which enhances activation of caspase-3 and caspase-9.
Subject(s)
Antineoplastic Agents/toxicity , Caspases/physiology , Cisplatin/toxicity , Kidney Tubules/drug effects , Protein Serine-Threonine Kinases , Animals , Apoptosis , CHO Cells , Cricetinae , Enzyme Activation , Epithelial Cells/drug effects , Phosphatidylinositol 3-Kinases/physiology , Phosphorylation , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-aktSubject(s)
Abscess/surgery , Neck Injuries/surgery , Streptococcal Infections/surgery , Streptococcus pyogenes , Wounds, Nonpenetrating/surgery , Abscess/diagnostic imaging , Adult , Drainage , Humans , Male , Neck Injuries/diagnostic imaging , Neck Muscles/diagnostic imaging , Neck Muscles/surgery , Streptococcal Infections/diagnostic imaging , Tomography, X-Ray Computed , Wounds, Nonpenetrating/diagnostic imagingABSTRACT
We have recently demonstrated an important pathogenic role for glomerular catalytic iron in the puromycin aminonucleoside (PAN) induced minimal change nephrotic syndrome (MCNS). The source of this iron capable of catalyzing free radical reactions is not known. We examined the role of cytochrome P-450 (CYP) as a source of catalytic iron in a model MCNS induced by single injection of PAN to rats. Treatment of PAN resulted in a marked increase in the catalytic iron associated with significant loss of glomerular CYP content. Administration of CYP inhibitors significantly prevented the injury-induced loss of CYP content and the increase in the catalytic iron in the glomeruli accompanied by a marked decrease in proteinuria. In an in vitro study utilizing glomerular epithelial cells (GEC), CYP inhibitors also markedly prevented the PAN-induced increase in the catalytic iron and hydroxyl radical formation accompanied by significant protection against PAN-induced cytotoxicity. Taken together our data indicate that the CYP, a group of heme protein, may serve as a significant source of this catalytic iron.
Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Iron/metabolism , Kidney Glomerulus/metabolism , Nephrotic Syndrome/metabolism , Animals , Cimetidine/pharmacology , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Kidney Glomerulus/drug effects , Male , Nephrotic Syndrome/chemically induced , Piperonyl Butoxide/pharmacology , Proteinuria , Puromycin Aminonucleoside , Ranitidine/pharmacology , Rats , Rats, Sprague-Dawley , Urothelium/metabolismABSTRACT
Puromycin aminonucleoside (PAN) administration in rats produces an experimental model of nephrotic syndrome characterized by glomerular epithelial cell injury and proteinuria. The purpose of this study was to examine the role of nitric oxide (NO) in this model of minimal change glomerular disease. Aminoguanidine (AG) was used to inhibit inducible nitric oxide synthase (iNOS). Sprague-Dawley rats were divided into Control (N = 9), PAN (N = 14), AG (N = 2), and PAN + AG (N = 12) treatment groups. Control animals received saline (i.v. ), PAN animals received PAN (75 mg/kg, i.v.), and PAN + AG animals received PAN plus AG (50 mg/kg, i.p., twice daily). AG animals received a saline injection (i.v.) on day 0 in the place of PAN and then AG on the same schedule as the PAN + AG group. Animals were kept in metabolic cages, and urinary protein excretion and nitrite (NO(2)(-)) excretion were measured daily. PAN administration increased urinary NO(2)(-) excretion by day 2, and levels remained elevated through day 7. AG prevented this PAN-induced increase in urinary NO(2)(-) excretion. Plasma nitrate (NO(3)(-)) and NO(2)(-) (NOx) concentrations were also increased in the PAN and PAN + AG groups. iNOS protein expression was not detected in either the glomeruli or the cortex at day 7. Proteinuria developed in PAN animals on day 4 and increased steadily through day 7. PAN + AG animals showed a pattern similar to that of the PAN group. These results indicated that in contrast to models of proliferative glomerulonephritis, NO formation during PAN-induced nephrotic syndrome is increased but does not participate in the development of glomerular injury as measured by proteinuria.